Objective: To analyse the anatomical, functional and quality-of-life results when using bioactive glass in mastoid and epitympanic obliteration. Design: Prospective clinical study. Setting: Tertiary referral centre. Participants: Forty-one cases (39 patients) operated between May 2013 and January 2015. Main outcome measures: Anatomical results were evaluated by otomicroscopy 1 year after surgery and using imaging to detect residual disease. Functional results were studied by postoperative hearing gain. Quality of life was assessed with the Glasgow Benefit Inventory questionnaire and the success of surgery by a surgery-specific questionnaire. Results: At 1 year, all patients presented a well-healed external auditory canal, with an intact tympanic membrane. In cases with cholesteatoma (n = 23), no recurrent retraction pockets or residual disease were observed on imaging studies. The overall air-bone gap closure was 7.7 AE 1.84 dB (mean AE SE of the mean, P < 0.001, paired ttest). No significant differences were found on hearing results when comparing primary versus revision surgery, canal-wall-up versus canal-wall-down obliterations, type of tympanoplasty and presence of cholesteatoma (multifactor ANOVA). The Glasgow Benefit Inventory improved with an average score of 28 and the success of surgery questionnaire showed a significant improvement in ear discharge and a moderate improvement in hearing and equilibrium. Conclusions: The use of bioactive glass for mastoid and epitympanic obliteration in canal-wall-down or canal-wallup tympanoplasties is an effective procedure in both primary and revision surgery. The anatomical and functional results appear to be well correlated with patient experience and to the improvement in quality of life.
Mastoid and epitympanic obliteration has been proposed for the rehabilitation of a canal-wall-down mastoidectomy to avoid cavity-related drawbacks. Otorrhoea, difficulty in fitting a hearing aid when needed and vertigo or imbalance due to thermal stimulation of the posterior labyrinth are often undesirable outcomes of a canal-wall-down mastoidectomy. [1] [2] [3] Obliteration has also been performed in canal-wall-up mastoidectomy, although less frequently, to reduce the recurrence and residual rate of cholesteatoma in adults and children 4, 5 and to facilitate middle ear aeration 6 after a closed technique with insufficient postoperative middle ear aeration. In both canal-wall-down and canalwall-up mastoidectomies, obliteration of the paratympanic spaces reduces the mucosal surface thus slowing gas absorption and pressure changes responsible for recurrence and improving long-term surgical outcome. 6 Many materials have been used for obliteration, either autologous (cartilage, bone pat e, bone chips, fat, muscular flaps) or biocompatible (bone substitutes, titanium, silicon blocks, hydroxyapatite cement). The bioactive glass S53P4 (BG) is a bone-substitute, silica-based biomaterial composed of a mixture of oxides (53% SiO 2 , 23% Na 2 O, 20% CaO and 4% P 2 O 5 ). It is osteoconductive and osteoproductive 7 and has the unique property of being antibacterial to many aerobic, anaerobic and multiresistant bacteria. 8 The 9 Beside these interesting properties, which have established the material as a first-line choice when using biocompatible materials in obliterative surgeries, only three reports [10] [11] [12] have been published concerning ear surgery, and only one was a prospective study. The safety of the granules of BG with regard to inner ear and skin tolerance has already been published. 13 The aim of this prospective study was to analyse the anatomical, functional, radiological and quality-of-life results of mastoid and epitympanic obliteration using the BG in primary and revision canal-wall-down and canal-wallup mastoidectomies.
Materials and methods

Ethical considerations
This study was authorised by the ethical institutional board, and all patients gave their written consent for the use of their personal clinical data. The BG used in this clinical trial was produced by BonAliveâ Biomaterials Ltd (Turku, Finland) and was approved for clinical use in Europe in 2004 and in the United States in 2007.
Study design
This prospective, observational uncontrolled study was carried out between May 2013 and January 2015 in a tertiary referral centre. Inclusion criteria were all the canal-walldown (primary or revision) surgeries (Fig. 1a) performed in this period with obliteration using granules of BG and canalwall-up mastoidectomies requiring obliteration for the stabilisation of an attic reconstruction after a large atticotomy (Fig. 1b) .
The surgical technique has been described previously. 13 Briefly, in both canal-wall-up and canal-wall-down mastoidectomies, obliteration of the paratympanic spaces, using granules of BG of 0.5-0.8 mm in diameter, followed: 1 removal of the lesions (cholesteatoma and/or inflammatory mucosa); 2 extensive drilling of the cavities until healthy bone was reached with removal of all visible pathologic mucosa; 3 reconstruction of the middle ear (tympanic drum + ossiculoplasty when needed).
All of the BG granules in contact with the skin of the external auditory canal were carefully covered by cartilage and fibrous tissue. The type of tympanoplasty was classified as follows: type I (myringoplasty with no ossicular chain reconstruction), type II (partial ossicular replacement prosthesis used on an intact stapes), type III (total ossicular replacement prosthesis used on an intact footplate) and type IV (platinectomy with fibrous tissue interposition and placement of a total ossicular replacement prosthesis). Titanium prosthesis (Aerial Kurzâ, Tubingen, Germany) of adapted length was used when needed. Intraoperative intravenous antibioprophylaxis with amoxicillin/clavulanate was performed in all patients after having performed intraoperative bacteriological tests on otorrhoea, cholesteatoma matrix (if present), mastoid skin (in case of revision canal-wall-down procedure) and middle ear/mastoid mucosa. Oral treatment with amoxicillin/clavulanate was continued until it was adapted to the results of the intraoperative bacteriological test; if there were no pathogenic bacteria, antibiotherapy was stopped. If some pathogenic bacteria were found, the oral antibiotherapy was adapted to the antibiogram and delivered for 14 days following recommendations for chronic otitis 14 and cochlear implant surgeries 15 with mastoid obliteration. Ear drops of ofloxacine were administered to all patients for 1 month. Perioperative complications were noted, as well as the presence of cholesteatoma.
Anatomical results were evaluated with otomicroscopy 3 months and 1 year after surgery: the presence of a wellhealed external auditory canal with no visible granules of BG and an intact tympanic membrane was considered to indicate a successful procedure. In the case of cholesteatoma, a computed tomography (CT) scan and non-echoplanar diffusion-weighted magnetic resonance imaging (MRI) 16 were also performed 1 year after surgery to detect residual disease in the middle ear and/or in the filled spaces.
Functional results were evaluated using the air-bone gap (ABG) closure, defined as the difference between preoperative and postoperative ABG. The ABG was calculated as recommended by the committee on hearing and equilibrium using pure-tone audiometry (mean of 500, 1000, 2000, 4000 Hz) in both air-conduction and bone-conduction conditions.
Quality of life was evaluated 1 year after surgery through two questionnaires: the Glasgow Benefit Inventory (GBI) 17 and a surgery-specific questionnaire. 18 The GBI measures the changes in health status produced by surgery, and it was divided into three subgroups (general, social support and physical health) and the results were reported from À100 to +100 for each subgroup and for the global score with zero being no change as a result of the intervention, À100 maximal deterioration and +100 being maximum qualityof-life improvement.
The surgery-specific questionnaire encompassed four questions:
1 Compared with before your ear surgery, how is your ear drainage? 2 Compared with before your ear surgery, how is your ear hearing? 3 Compared with before your ear surgery, how is your equilibrium? 4 Would you recommend this surgery to a family member?
The possible answers for the first three questions were noted using a Likert scale ranging from 1 to 5 (1 = dramatically worse; 2 = somewhat worse; 3 = not changed; 4 = somewhat improved; 5 = dramatically improved). For the last question, possible answers were as follows: 1 = would discourage; 2 = unlikely to recommend; 3 = indifferent; 4 = likely to recommend; 5 = highly recommended.
Statistical analysis
Data were presented as mean AE standard error of the mean (SEM). Comparison between pre-and postoperative results was performed with a paired t-test. A multifactor ANOVA was used to analyse the influence of different tympanoplasty subgroups (type I, II, III and IV), the presence or not of a cholesteatoma and primary versus revision surgery on ABG closure. Differences in quality of life (GBI scores) between primary and revision surgery were analysed using the Mann-Whitney U-test.
For all comparisons, P < 0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using IBM SPSS for Windows (v 22.0, SPSS Inc., Chicago, IL, USA).
Results
Participants
Forty-one cases (39 patients, two operated bilaterally) were included (Table 1) : there were 22 males and 17 females. The mean age was 46 AE 2.5 years (range 16-79 years). There were 25 right side and 16 left side cases. Thirty-six cases (88%) were revision surgeries; the median number of previous surgeries was two (range 1-5). Of these 36 revision cases, 26 cases (72%) had already been operated with a canal-wall-down mastoidectomy, whereas 10 (28%) were previously operated with an intact canal wall technique.
Intraoperative findings
Revision cases (n = 36) underwent revision canal-walldown mastoidectomy in 26 cases (72%), a canal-wall-down mastoidectomy in six cases (17%) and a canal-wall-up mastoidectomy in four cases (11%).
Primary cases (n = 5) were operated on with an open technique in three cases (60%) and with a closed technique in two cases (40%). Overall, an open technique was obliterated in 35 cases (85%), whereas a closed technique in six cases (15%). Tympanoplasty type I was performed in five cases (12%), type II in 19 cases (46%), type III in 14 cases (34%) and type IV in three cases (8%). Cholesteatoma was found in 23 cases (56%).
Perioperative complications occurred in seven cases (17%). There were six cases (15%) where an opening of the inner ear occurred during surgery: two cases of a preoperative identified fistula of the lateral semicircular In the canal-wall-down mastoidectomy (a), cartilage (white star) is used to cover the granules in the new external auditory canal filled with resorbable mesh (white arrow). In the canal-wall-up mastoidectomy (b), granules are used to stabilise the attic reconstruction after a large atticotomy (black arrow) after reconstruction of the middle ear with a titanium total ossicular replacement prosthesis (white arrow). canal, three cases of a fractured/absent stapes footplate who underwent type IV tympanoplasty and one case of round window membrane opening during dissection of the cholesteatoma invading the sinus tympani and hypotympanum. In one case (2%), cerebrospinal fluid (CSF) leakage occurred during dissection of the skin over a tegmen tympani defect.
Anatomical results
Three months after surgery, 34 cases (83%) presented a wellhealed external auditory canal with an intact tympanic drum (Fig. 2) ; two cases (5%) presented a narrow but functional external auditory canal with an intact tympanic drum. Four cases (10%) presented various degrees of lateralisation of the tympanic drum. Only one patient (2%) presented uncovered granules in the external auditory canal and underwent revision surgery 5 months after the first surgery, under local anaesthesia, to cover the granules with cartilage. At 1 year, he had a well-healed external auditory canal and tympanic drum. At 1 year after surgery, these results were unchanged. No cases of recurrent cholesteatoma and/or retraction pocket were observed. In the postoperative CT (Fig. 3) and MRI studies (n = 23), no residual disease was found at 1 year after surgery.
Functional results
Preoperative hearing status for each patient is detailed in Table 1 . The preoperative air-conduction and bone-conduction pure-tone averages were 59 AE 3.2 dB and 32 AE 2.7 dB, respectively. Patients with opening of the membrane of the round window experienced immediate total ipsilateral hearing loss. Postoperative pure-tone averages (n = 40, deaf patient excluded) were 47 AE 3.6 dB and 27 AE 2.8 dB for air and bone conduction, respectively. There was no statistically significant difference between pre-and postoperative bone-conduction threshold (paired t-test). The mean ABG closure was 7.7 AE 1.84 dB and the difference was statistically significant (P < 0.001, paired ttest). Detailed functional results following type of tympanoplasty, primary versus revision surgery, canal-wall-up versus canal-wall-down and presence versus absence of cholesteatoma are shown in Table 2 . No statistically significant differences were found in the ABG closure when comparing the different types of tympanoplasty, primary versus revision surgery, canal-wall-up versus canal-walldown procedures and the presence versus absence of cholesteatoma (NS, multifactor ANOVA).
Questionnaires
The overall quality of life improved after epitympanic or mastoid obliteration. The overall GBI score was 28 AE 3.6 (range À22 to 78); three patients had a negative score indicating a worsening of the quality of life. No statistically significant differences were found when comparing primary versus revision surgeries (Mann-Whitney U-test) ( Table 3) . Detailed results for each question are shown in Table 4 .
Regarding the surgery-specific questionnaire, the median values of the responses were 5, 4, 4 and 5 for discharge, hearing, equilibrium and recommendation, respectively, showing a significant improvement in the discharge of the ear felt by the patient. There was also a moderate improvement in hearing and equilibrium, and almost all patients highly recommended such an operation. Detailed results are shown in Table 5 .
Discussion
The goals of cholesteatoma surgery are the complete eradication of the disease, preventing a recurrence, and maintaining or restoring hearing. A canal-wall-down procedure is often the results of multiple operations to achieve these objectives, exposing the patient to cavityrelated problems.
Mastoid obliteration is used to reduce the recurrence and the residual rate in primary cholesteatoma surgery using both canal-wall-up 4, 5 and canal-wall-down procedures. 14, 19, 20 Moreover, obliteration of an unstable mastoid cavity leads to significantly better results for discharge, 1, 21, 22 hearing rehabilitation 23 and imbalance 3 than a revision canal-wall-down procedure. 24 Since 1911, 25 many materials, either autologous or biocompatible, have been used for obliteration. The disadvantages of using autologous materials are donor-site morbidity and the risk of resorption over time. 26 Using biocompatible materials, the most feared complication is infection and its subsequent extrusion. This is why the antibacterial activity of BG granules to the most frequent bacteria involved in chronic otitis seemed very attractive to us.
Synopsis of key findings
This study shows that the obliteration of both canal-wall-up and canal-wall-down procedures in primary or revision Mastoid obliteration with bioactive glass 393 surgery is an effective technique, and the initial results showed no adverse effects.
Regarding anatomical results, no infection of the implanted material has been reported with the necessity for removal of the BG granules. An intact external auditory canal with a well-healed tympanic membrane was achieved in most of our patients. Various degrees of lateralisation of the tympanic membrane can be expected, especially in multioperated ears. A narrow external auditory canal was found in two cases; this was probably the result of the bulging of the posterosuperior wall of the external auditory canal that is sometimes observed 1 month after surgery; in such a case, an insertion of an expandable sponge packing with eardrops containing corticosteroids for 2 weeks can help in achieving an appropriate conformation of the external auditory canal.
No recurrence was seen within the study follow-up period (with a maximum follow-up of 3 years) or residual disease in postoperative imaging studies.
Regarding functional results, an overall improvement in hearing was achieved, even though not spectacular. Considering that most of our cases were revision surgeries, our results are in line with the reported literature, 14, 20, 26 and the reconstructed external auditory canal allowed changes in external ear resonance 27 and facilitated the use of hearing aids. 23 For quality of life, an overall significant improvement was observed in all procedures. The results of the GBI questionnaires are similar to those obtained in other studies 18, 28 with a significant improvement in quality of life, and this improvement is similar when considering primary and revision cases. Results for the surgery-specific questionnaire showed a marked improvement in the discharge of the ear, and mild or no improvement in hearing and balance, thus permitting a good correlation between objective and subjective results.
Comparison with other studies
Only three studies have been published which use BG in ear surgery, but none simultaneously report anatomical, functional and quality-of-life results. In 2010, Stoor et al. 10 retrospectively analysed seven cases of obliteration of discharging cavities reporting good skin tolerance and no infection of the implanted material. In 2012, 12 the same department retrospectively analysed 25 cases (including the seven cases previously published with longer follow-up) treated over a 15 year period; 92% of patients have a dry smaller cavity after the operation but no statistical analysis was performed with regard to hearing. Finally, the only prospective study was performed by Silvola 11 who reported on 14 patients treated with BG granules between 2007 and 2011 using different surgical techniques; he achieved a dry ear in all patients.
Strengths of the study
To our knowledge, this is the first prospective study on a large cohort of patients treated for mastoid and epitympanic obliteration in a short time with the same surgical technique. Analysing both objective and subjective data allows a better comprehension and evaluation of the results, both anatomically and functionally. The quality of life and success of surgery questionnaires are essential when reporting results in chronic ear surgery.
Study limitations
The short 1 year follow-up is the main limitation of the study, especially when considering recurrence/residual results, but this is inevitable when performing a prospective study in a tertiary referral centre. For patients with longer follow-up, anatomical results remain stable, but 5 year follow-up is necessary to evaluate the long-term results of the obliteration.
Moreover, the results of questionnaires could be overrated due to patient complacency.
Clinical applicability of the study Despite its limitations, this study demonstrates that BG is an effective material for mastoid and epitympanic obliteration with no infection in the present series and with anatomical and functional results that are well correlated with the improvement in quality of life.
Key points
• Bioactive glass for mastoid and epitympanic obliteration in canal-wall-down or canal-wall-up tympanoplasties is an effective procedure in both primary and revision surgery.
• The anatomical and functional results appear to be well correlated with patient experience and to the improvement in quality of life.
• Even if a marked improvement of the hearing is difficult to achieve in multi-operated ears, the anatomical reconstruction might facilitate the use of a conventional hearing aid.
